Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma

Br J Haematol. 2023 Mar;200(6):824-827. doi: 10.1111/bjh.18657. Epub 2023 Jan 17.

Authors

Luciano J Costa¹, Smith Giri¹, Susan Bal¹, Gayathri Ravi¹, Kelly N Godby¹

Affiliation

¹ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

PMID: 36649972
DOI: 10.1111/bjh.18657

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Neoplasms, Plasma Cell*
Thalidomide / therapeutic use

Substances

Thalidomide
Dexamethasone